N@N

ALAMEDA, Calif.--([ BUSINESS WIRE ])--InSite Vision Incorporated (OTCBB:INSV) today announced that its Chief Executive Officer, Timothy Ruane, will speak at the 23^rd Annual Piper Jaffray Health Care Conference on November 30, 2011 at 3:30 pm ET at The New York Palace Hotel in New York City.

About InSite Vision

InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The companyas product portfolio utilizes InSite Visionas proven DuraSite bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Visionas clinical-stage ophthalmic product pipeline includes AzaSite Plus^a" (ISV-502) and DexaSite^a" (ISV-305) for the treatment of eye infections, BromSite^a" (ISV-303) for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit [ www.insitevision.com ].

AzaSite and DuraSite are registered trademarks of InSite Vision Incorporated.

BESIVANCE is a registered trademark of Bausch & Lomb Incorporated.